You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePiroxicam
Accession NumberDB00554  (APRD01187)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]
Structure
Thumb
Synonyms
4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
Feldene
Piroxicam
Piroxicamum
Pyroxycam
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-piroxicam-cap 10mgcapsule10 mgoralAltimed Pharma Inc.1997-09-242004-08-03Canada
Alti-piroxicam-cap 20mgcapsule20 mgoralAltimed Pharma Inc.1995-12-312004-08-03Canada
Dom-piroxicamsuppository10 mgrectalDominion Pharmacal1995-12-31Not applicableCanada
Dom-piroxicamcapsule20 mgoralDominion Pharmacal1999-10-25Not applicableCanada
Dom-piroxicamsuppository20 mgrectalDominion Pharmacal1995-12-31Not applicableCanada
Dom-piroxicamcapsule10 mgoralDominion PharmacalNot applicableNot applicableCanada
Feldenecapsule10 mg/1oralPfizer Laboratories Div Pfizer Inc1994-05-25Not applicableUs
Feldenecapsule20 mg/1oralPfizer Laboratories Div Pfizer Inc1994-05-25Not applicableUs
Feldenecapsule20 mg/1oralREMEDYREPACK INC.2012-09-26Not applicableUs
Feldene Cap 10mgcapsule10 mgoralPfizer Canada Inc1981-12-312002-09-06Canada
Feldene Cap 20mgcapsule20 mgoralPfizer Canada Inc1981-12-312002-07-25Canada
Feldene Sup 10mgsuppository10 mgrectalPfizer Canada Inc1986-12-311999-08-10Canada
Feldene Sup 20mgsuppository20 mgrectalPfizer Canada Inc1986-12-312002-07-25Canada
Fexicamsuppository20 mgrectalTechnilab Pharma Inc.1998-08-172004-08-03Canada
Gen-piroxicam - Cap 20mgcapsule20 mgoralGenpharm Ulc1995-12-312010-08-04Canada
Gen-piroxicam-cap 10mgcapsule10 mgoralGenpharm Ulc1995-12-312010-08-04Canada
Nu-pirox Cap 10mgcapsule10 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-pirox Cap 20mgcapsule20 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Penta-piroxicam Capsulescapsule20 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-piroxicam Capsulescapsule10 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Piroxicamcapsule20 mg/1oralGreenstone LLC2014-03-03Not applicableUs
Piroxicamcapsule10 mg/1oralGreenstone LLC2014-03-03Not applicableUs
Piroxicam Capsules 10mgcapsule10 mgoralPrempharm Inc1997-01-052005-08-05Canada
Piroxicam Capsules 20mgcapsule20 mgoralPrempharm Inc1997-01-052005-08-05Canada
PMS-piroxicamcapsule20 mgoralPharmascience Inc1996-12-31Not applicableCanada
PMS-piroxicamcapsule10 mgoralPharmascience Inc1996-12-31Not applicableCanada
PMS-piroxicam Suppositories -20mgsuppository20 mgrectalPharmascience Inc1995-12-31Not applicableCanada
PMS-piroxicam Suppositories-10mgsuppository10 mgrectalPharmascience Inc1995-12-31Not applicableCanada
Pro-piroxicam Cap 10mgtablet10 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Pro-piroxicam Cap 20mgcapsule20 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Rho-piroxicam - 10mg Capcapsule10 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-piroxicam - Cap 20mgcapsule20 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Teva-piroxicamcapsule20 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Teva-piroxicamcapsule10 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Piroxicam Cap 10mgcapsule10 mgoralApotex Inc1986-12-31Not applicableCanada
Apo Piroxicam Cap 20mgcapsule20 mgoralApotex Inc1986-12-31Not applicableCanada
Feldenecapsule20 mg/1oralKeltman Pharmaceuticals Inc.2007-09-18Not applicableUs
Piroxicamcapsule10 mg/1oralRebel Distributors Corp2009-11-12Not applicableUs
Piroxicamcapsule10 mg/1oralPhysicians Total Care, Inc.2005-01-21Not applicableUs
Piroxicamcapsule20 mg/1oralSTAT Rx USA LLC2011-10-07Not applicableUs
Piroxicamcapsule10 mg/1oralTeva Pharmaceuticals USA Inc1994-10-19Not applicableUs
Piroxicamcapsule20 mg/1oralbryant ranch prepack2010-01-05Not applicableUs
Piroxicamcapsule20 mg/1oralRebel Distributors Corp2010-01-05Not applicableUs
Piroxicamcapsule20 mg/1oralSun Pharmaceutical Industries, Inc.1993-03-12Not applicableUs
Piroxicamcapsule10 mg/1oralSTAT Rx USA LLC2010-11-02Not applicableUs
Piroxicamcapsule20 mg/1oralH.J. Harkins Company, Inc.2012-04-16Not applicableUs
Piroxicamcapsule20 mg/1oralPhysicians Total Care, Inc.1994-10-06Not applicableUs
Piroxicamcapsule10 mg/1oralREMEDYREPACK INC.2013-03-20Not applicableUs
Piroxicamcapsule20 mg/1oralREMEDYREPACK INC.2011-04-12Not applicableUs
Piroxicamcapsule20 mg/1oralTeva Pharmaceuticals USA Inc1994-01-26Not applicableUs
Piroxicamcapsule10 mg/1oralbryant ranch prepack2010-01-05Not applicableUs
Piroxicamcapsule10 mg/1oralRebel Distributors Corp2010-01-05Not applicableUs
Piroxicamcapsule10 mg/1oralGolden State Medical Supply, Inc.2010-01-05Not applicableUs
Piroxicamcapsule20 mg/1oralSTAT Rx USA LLC2010-11-02Not applicableUs
Piroxicamcapsule10 mg/1oralH.J. Harkins Company, Inc.2012-04-16Not applicableUs
Piroxicamcapsule20 mg/1oralPd Rx Pharmaceuticals, Inc.2010-11-02Not applicableUs
Piroxicamcapsule10 mg/1oralNostrum Laboratories, Inc.2010-01-05Not applicableUs
Piroxicamcapsule10 mg/1oralPACK Pharmaceuticals, LLC2010-06-15Not applicableUs
Piroxicamcapsule20 mg/1oralAphena Pharma Solutions Tennessee, Llc1994-01-26Not applicableUs
Piroxicamcapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC1994-01-26Not applicableUs
Piroxicamcapsule10 mg/1oralAv Kare, Inc.2013-06-27Not applicableUs
Piroxicamcapsule20 mg/1oralGolden State Medical Supply, Inc.2010-01-05Not applicableUs
Piroxicamcapsule20 mg/1oralRebel Distributors Corp2009-11-12Not applicableUs
Piroxicamcapsule10 mg/1oralAvera Mc Kennan Hospital2015-11-10Not applicableUs
Piroxicamcapsule20 mg/1oralA S Medication Solutions Llc2010-01-05Not applicableUs
Piroxicamcapsule20 mg/1oralNostrum Laboratories, Inc.2010-01-05Not applicableUs
Piroxicamcapsule10 mg/1oralSun Pharmaceutical Industries, Inc.1993-03-12Not applicableUs
Piroxicamcapsule20 mg/1oralPACK Pharmaceuticals, LLC2010-06-15Not applicableUs
Piroxicamcapsule20 mg/1oralUnit Dose Services2010-01-05Not applicableUs
Piroxicamcapsule20 mg/1oralAv Kare, Inc.2012-11-28Not applicableUs
Piroxicamcapsule20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Piroxicamcapsule10 mg/1oralNorthstar Rx LLC2016-02-152016-03-19Us
Piroxicamcapsule20 mg/1oralNorthstar Rx LLC2016-02-152016-03-19Us
Piroxicamcapsule10 mg/1oralNivagen Pharmaceuticals, Inc2016-02-152016-03-29Us
Piroxicamcapsule20 mg/1oralNivagen Pharmaceuticals, Inc2016-02-152016-03-29Us
International Brands
NameCompany
BruxicamNot Available
DolonexNot Available
ErazonNot Available
GeldèneNot Available
ImprontalNot Available
RoxamBosnalijek
RoxidenNot Available
SasulenNot Available
SolocalmNot Available
TrastNot Available
Brand mixtures
NameLabellerIngredients
TherafeldaminePhysician Therapeutics Llc
SaltsNot Available
Categories
UNII13T4O6VMAM
CAS number36322-90-4
WeightAverage: 331.346
Monoisotopic: 331.062676609
Chemical FormulaC15H13N3O4S
InChI KeyInChIKey=QYSPLQLAKJAUJT-UHFFFAOYSA-N
InChI
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
IUPAC Name
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassNot Available
Direct ParentBenzothiazines
Alternative Parents
Substituents
  • N-arylamide
  • Benzothiazine
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • Ortho-thiazine
  • Heteroaromatic compound
  • Vinylogous acid
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of osteoarthritis and rheumatoid arthritis.
PharmacodynamicsPiroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
Mechanism of actionThe antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.
Related Articles
AbsorptionWell absorbed following oral administration.
Volume of distribution
  • 0.14 L/kg
Protein bindingNot Available
Metabolism

Renal

SubstrateEnzymesProduct
Piroxicam
5'-HydroxypiroxicamDetails
Route of eliminationPiroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.
Half life30 to 86 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Piroxicam Action PathwayDrug actionSMP00077
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9898
Blood Brain Barrier-0.9659
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5786
P-glycoprotein inhibitor INon-inhibitor0.7285
P-glycoprotein inhibitor IINon-inhibitor0.7453
Renal organic cation transporterNon-inhibitor0.9437
CYP450 2C9 substrateSubstrate0.6437
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7356
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.9086
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8709
Ames testNon AMES toxic0.8767
CarcinogenicityNon-carcinogens0.7612
BiodegradationNot ready biodegradable0.923
Rat acute toxicity3.1545 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.8311
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akorn inc
  • Pfizer laboratories div pfizer inc
  • Egis pharmaceuticals
  • Genpharm pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Roxane laboratories inc
  • Scs pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg/1
Capsuleoral20 mg/1
Capsuleoral10 mg
Capsuleoral20 mg
Suppositoryrectal20 mg
Suppositoryrectal10 mg
Tabletoral10 mg
Kit
Prices
Unit descriptionCostUnit
Piroxicam powder13.16USD g
Akten 3.5% drops7.5USD ml
Feldene 20 mg capsule4.93USD capsule
Feldene 10 mg capsule2.82USD capsule
Piroxicam 20 mg capsule2.69USD capsule
Pms-Piroxicam 20 mg Suppository1.82USD suppository
Piroxicam 10 mg capsule1.44USD capsule
Apo-Piroxicam 20 mg Capsule0.75USD capsule
Novo-Pirocam 20 mg Capsule0.75USD capsule
Nu-Pirox 20 mg Capsule0.75USD capsule
Apo-Piroxicam 10 mg Capsule0.43USD capsule
Gen-Piroxicam 10 mg Capsule0.43USD capsule
Novo-Pirocam 10 mg Capsule0.43USD capsule
Nu-Pirox 10 mg Capsule0.43USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point198-200 °CPhysProp
water solubility23 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.06AVDEEF,A (1997)
logS-4.16ADME Research, USCD
Caco2 permeability-4.45ADME Research, USCD
pKa6.3SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP2.2ALOGPS
logP0.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.76ChemAxon
pKa (Strongest Basic)3.79ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.04 m3·mol-1ChemAxon
Polarizability32.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Paul D. Weeks, “3-Hydroxy 2-methyl benzisothiazolines as intermediates in production of piroxicam.” U.S. Patent US4376204, issued April, 1982.

US4376204
General ReferencesNot Available
External Links
ATC CodesS01BC06M02AA07M01AC01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (74.3 KB)
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
AbciximabPiroxicam may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Piroxicam can be increased when it is combined with Abiraterone.
AcebutololPiroxicam may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aceclofenac.
AcenocoumarolPiroxicam may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Piroxicam.
Alendronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.
AliskirenPiroxicam may decrease the antihypertensive activities of Aliskiren.
AlprenololPiroxicam may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Piroxicam.
AmikacinPiroxicam may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmiloridePiroxicam may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Piroxicam can be decreased when combined with Amiodarone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Piroxicam.
AncrodPiroxicam may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.
Antithrombin III humanPiroxicam may increase the anticoagulant activities of Antithrombin III human.
ApixabanPiroxicam may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Apremilast.
AprepitantThe metabolism of Piroxicam can be increased when combined with Aprepitant.
ArdeparinPiroxicam may increase the anticoagulant activities of Ardeparin.
ArgatrobanPiroxicam may increase the anticoagulant activities of Argatroban.
ArotinololPiroxicam may decrease the antihypertensive activities of Arotinolol.
AtenololPiroxicam may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Piroxicam.
BalsalazidePiroxicam may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Piroxicam.
BecaplerminPiroxicam may increase the anticoagulant activities of Becaplermin.
BefunololPiroxicam may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Piroxicam.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piroxicam.
BenoxaprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Benoxaprofen.
BetaxololPiroxicam may decrease the antihypertensive activities of Betaxolol.
BevantololPiroxicam may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Piroxicam.
BisoprololPiroxicam may decrease the antihypertensive activities of Bisoprolol.
BivalirudinPiroxicam may increase the anticoagulant activities of Bivalirudin.
BopindololPiroxicam may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bromfenac.
BufuralolPiroxicam may decrease the antihypertensive activities of Bufuralol.
BumetanidePiroxicam may decrease the diuretic activities of Bumetanide.
BupranololPiroxicam may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Piroxicam.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Piroxicam.
CapecitabineThe metabolism of Piroxicam can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Piroxicam.
CarbamazepineThe metabolism of Piroxicam can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Piroxicam.
CarprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Carprofen.
CarteololPiroxicam may decrease the antihypertensive activities of Carteolol.
CarvedilolPiroxicam may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Piroxicam.
CeliprololPiroxicam may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Piroxicam can be increased when it is combined with Ceritinib.
CertoparinPiroxicam may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Piroxicam.
CholecalciferolThe metabolism of Piroxicam can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Piroxicam.
Citric AcidPiroxicam may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clonixin.
ClopidogrelThe metabolism of Piroxicam can be decreased when combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Piroxicam.
ClotrimazoleThe metabolism of Piroxicam can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporinePiroxicam may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Piroxicam can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Piroxicam is combined with D-Limonene.
Dabigatran etexilatePiroxicam may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib.
DalteparinPiroxicam may increase the anticoagulant activities of Dalteparin.
DanaparoidPiroxicam may increase the anticoagulant activities of Danaparoid.
DaunorubicinPiroxicam may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Piroxicam is combined with Deferasirox.
DeferasiroxThe serum concentration of Piroxicam can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Piroxicam can be decreased when combined with Delavirdine.
DesirudinPiroxicam may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Piroxicam.
DextranPiroxicam may increase the anticoagulant activities of Dextran.
Dextran 40Piroxicam may increase the anticoagulant activities of Dextran 40.
Dextran 70Piroxicam may increase the anticoagulant activities of Dextran 70.
Dextran 75Piroxicam may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diclofenac.
DicoumarolPiroxicam may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Piroxicam.
DihydrostreptomycinPiroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Piroxicam.
DoxorubicinPiroxicam may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenonePiroxicam may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Droxicam.
Edetic AcidPiroxicam may increase the anticoagulant activities of Edetic Acid.
EdoxabanPiroxicam may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Piroxicam can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Piroxicam.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Piroxicam.
EnoxaparinPiroxicam may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Piroxicam is combined with Epirizole.
EpirubicinPiroxicam may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenonePiroxicam may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Piroxicam.
EsmololPiroxicam may decrease the antihypertensive activities of Esmolol.
Etacrynic acidPiroxicam may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Piroxicam.
Ethyl biscoumacetatePiroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.
EtravirineThe metabolism of Piroxicam can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Piroxicam is combined with exisulind.
FelodipineThe metabolism of Piroxicam can be decreased when combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Piroxicam.
FloxuridineThe metabolism of Piroxicam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Piroxicam can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flunixin.
FluorouracilThe metabolism of Piroxicam can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurbiprofen.
FluvastatinThe metabolism of Piroxicam can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Piroxicam can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Piroxicam.
Fondaparinux sodiumPiroxicam may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Piroxicam.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Piroxicam.
FosphenytoinThe metabolism of Piroxicam can be increased when combined with Fosphenytoin.
FramycetinPiroxicam may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemidePiroxicam may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Piroxicam.
GemfibrozilThe metabolism of Piroxicam can be decreased when combined with Gemfibrozil.
GentamicinPiroxicam may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.
HeparinPiroxicam may increase the anticoagulant activities of Heparin.
HirulogPiroxicam may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Piroxicam is combined with HMPL-004.
HydralazinePiroxicam may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piroxicam.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Piroxicam.
Hygromycin BPiroxicam may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Piroxicam is combined with Icatibant.
IdarubicinPiroxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Piroxicam.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.
IndenololPiroxicam may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Piroxicam can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.
IndoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Piroxicam.
IsoxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Isoxicam.
KanamycinPiroxicam may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Kebuzone.
KetoconazoleThe metabolism of Piroxicam can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Piroxicam.
LabetalolPiroxicam may decrease the antihypertensive activities of Labetalol.
LapatinibThe metabolism of Piroxicam can be decreased when combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Leflunomide.
LepirudinPiroxicam may increase the anticoagulant activities of Lepirudin.
LevobunololPiroxicam may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Piroxicam.
LithiumThe serum concentration of Lithium can be increased when it is combined with Piroxicam.
LopinavirThe metabolism of Piroxicam can be decreased when combined with Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Piroxicam.
LovastatinThe metabolism of Piroxicam can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Piroxicam.
LumacaftorThe serum concentration of Piroxicam can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Piroxicam.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.
MesalazinePiroxicam may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Piroxicam.
MetamizoleThe risk or severity of adverse effects can be increased when Piroxicam is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Piroxicam.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.
MetipranololPiroxicam may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.
MetoprololPiroxicam may decrease the antihypertensive activities of Metoprolol.
MetrizamidePiroxicam may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Piroxicam can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Piroxicam.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Piroxicam.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Piroxicam.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Piroxicam.
NadololPiroxicam may decrease the antihypertensive activities of Nadolol.
NadroparinPiroxicam may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Piroxicam is combined with NCX 4016.
NeomycinPiroxicam may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nepafenac.
NetilmicinPiroxicam may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Piroxicam can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Niflumic Acid.
NilotinibThe metabolism of Piroxicam can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Piroxicam.
OlopatadineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Olopatadine.
OlsalazinePiroxicam may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Piroxicam.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Piroxicam.
OmeprazoleThe metabolism of Piroxicam can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Orgotein.
OtamixabanPiroxicam may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.
OxprenololPiroxicam may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Parecoxib.
ParomomycinPiroxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololPiroxicam may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfatePiroxicam may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Piroxicam.
PhenindionePiroxicam may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Piroxicam can be increased when combined with Phenobarbital.
PhenprocoumonPiroxicam may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Phenylbutazone.
PhenytoinThe metabolism of Piroxicam can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Piroxicam.
PindololPiroxicam may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Piroxicam can be decreased when combined with Pioglitazone.
PiretanidePiroxicam may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pirfenidone.
PlicamycinPiroxicam may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Piroxicam.
PractololPiroxicam may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Piroxicam.
PrimidoneThe metabolism of Piroxicam can be increased when combined with Primidone.
ProbenecidThe serum concentration of Piroxicam can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Propacetamol.
PropranololPiroxicam may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Piroxicam.
Protein CPiroxicam may increase the anticoagulant activities of Protein C.
ProtocatechualdehydePiroxicam may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Piroxicam is combined with PTC299.
PuromycinPiroxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Piroxicam can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Piroxicam.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Piroxicam.
QuinineThe metabolism of Piroxicam can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Piroxicam can be decreased when combined with Rabeprazole.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Piroxicam.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Piroxicam.
ResveratrolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.
ReviparinPiroxicam may increase the anticoagulant activities of Reviparin.
RibostamycinPiroxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Piroxicam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Piroxicam can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Risedronate.
RitonavirThe metabolism of Piroxicam can be decreased when combined with Ritonavir.
RivaroxabanPiroxicam may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Piroxicam.
RosiglitazoneThe metabolism of Piroxicam can be decreased when combined with Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Piroxicam.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Piroxicam.
SecobarbitalThe metabolism of Piroxicam can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Seratrodast.
SildenafilThe metabolism of Piroxicam can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Piroxicam can be decreased when combined with Sorafenib.
SotalolPiroxicam may decrease the antihypertensive activities of Sotalol.
SpectinomycinPiroxicam may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Piroxicam.
SpironolactonePiroxicam may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Piroxicam is combined with SRT501.
StiripentolThe metabolism of Piroxicam can be decreased when combined with Stiripentol.
StreptomycinPiroxicam may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinPiroxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Piroxicam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfamethoxazole.
SulfasalazinePiroxicam may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Piroxicam.
SulfisoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulindac.
SulodexidePiroxicam may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suprofen.
TacrolimusPiroxicam may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Piroxicam.
TamoxifenThe metabolism of Piroxicam can be decreased when combined with Tamoxifen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Piroxicam.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Piroxicam.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Piroxicam.
TenofovirThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Piroxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Piroxicam can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Piroxicam can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiludronate.
TimololPiroxicam may decrease the antihypertensive activities of Timolol.
TobramycinPiroxicam may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Piroxicam can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Piroxicam.
TorasemidePiroxicam may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Piroxicam.
TranilastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Piroxicam.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Piroxicam.
TriamterenePiroxicam may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Piroxicam.
TrimethoprimThe metabolism of Piroxicam can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Valdecoxib.
Valproic AcidThe metabolism of Piroxicam can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Piroxicam.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Piroxicam.
VoriconazoleThe metabolism of Piroxicam can be decreased when combined with Voriconazole.
WarfarinPiroxicam may increase the anticoagulant activities of Warfarin.
XimelagatranPiroxicam may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Piroxicam can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zomepirac.
Food Interactions
  • Take with food. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774 ]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163 ]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155 ]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774 ]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163 ]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155 ]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
  5. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, Endou H: Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999 Jun;289(3):1301-5. [PubMed:10336520 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  3. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23